Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer
Status:
Suspended
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and immune response of
different doses of URLC10 peptide emulsified with Montanide ISA51 in combination with
gemcitabine. Recommended phase II dose will be also determined.
Phase:
Phase 1
Details
Lead Sponsor:
Akita University Hospital
Collaborator:
Human Genome Center, Institute of Medical Science, University of Tokyo